InvestorsHub Logo
Followers 3
Posts 609
Boards Moderated 0
Alias Born 11/09/2017

Re: None

Wednesday, 07/17/2019 4:15:43 PM

Wednesday, July 17, 2019 4:15:43 PM

Post# of 50157
“This capital investment is our
most significant financing in two years. With this transaction we have positioned the Company to complete enrollment for the Registration trial in ocular
melanoma liver metastases, which we believe may be able to release top line data in 2020. We have worked very closely with fundamental investors
who believe in our therapy and the potential it represents in ocular melanoma.

My opinion is not a recommendation to buy or sell any security. Your decision whether or not to make a purchase or sell should be based on your own due diligence.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DCTH News